Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FIRST: Fisetin to Reduce Senescence and Mobility Impairment in PAD
NCT06399809Phase 2Recruiting
- Sponsor
- Northwestern University
- Start
- Sep 2024
- Primary completion
- Nov 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of fisetin in peripheral artery disease (PAD), sponsored by Northwestern University. Started Sep 2024; status: recruiting.
02
Drugs
fisetin
03
Conditions
peripheral artery disease (PAD)
Beyond the preview
Go deeper on NCT06399809.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06399809.